or DVd, as a second line or later treatment for relapsed or refractory multiple myeloma. A planned interim analysis of the study, called DREAMM-7, showed a statistically significant 42% reduction ...

There was also a 2.5-fold increase over DVd on the proportion of patients ... shift" in the treatment of relapsed or refractory multiple myeloma. GSK has also said it plans to continue working ...

Saad Usmani, Chief of MSK's Myeloma Service, says there are far more treatment options for multiple myeloma today compared with just 20 years ago. Note: This story was originally published in 2022 and ...